The cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy in patients with large B-cell lymphoma in Sweden

Real-World Manufacturing Experience of Axicabtagene Ciloleucel for Patients Treated in Second Line Versus Third Line of Therapy and Beyond

Real-World Safety Outcomes of Axicabtagene Ciloleucel in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Europe and United States: A Systematic Review and Meta-Analysis

Cost-effectiveness and Budget Impact Analyses of Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma in Singapore

ZUMA-24 Preliminary Analysis: A Phase 2 Study of Axicabtagene Ciloleucel in the Outpatient Setting With Prophylactic Corticosteroids in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada

Treatment Preferences and Quality of Life in Patients with Relapsed / Refractory Follicular Lymphoma

Phase 1 Study Of CART-ddBCMA For The Treatment Of Patients With Relapsed And/Or Refractory Multiple Myeloma: Results From At Least 1-year Follow-up In All Patients

Updated Trends in Real-World Outpatient Administration of Axicabtagene Ciloleucel and Brexucabtagene Autoleucel in Relapsed/Refractory Non-Hodgkin Lymphoma